Paratek Pharmaceuticals, Inc.

NasdaqGM:PRTK Voorraadrapport

Marktkapitalisatie: US$127.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Paratek Pharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 1/6

Paratek Pharmaceuticals has a total shareholder equity of $-201.4M and total debt of $258.3M, which brings its debt-to-equity ratio to -128.3%. Its total assets and total liabilities are $145.8M and $347.2M respectively.

Belangrijke informatie

-128.3%

Verhouding schuld/eigen vermogen

US$258.33m

Schuld

Rente dekkingsration/a
ContantUS$42.69m
Aandelen-US$201.36m
Totaal verplichtingenUS$347.16m
Totaal activaUS$145.79m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Apr 17
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Paratek Pharmaceuticals: Patience Is Wearing Thin

Aug 24

Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M

Aug 03

Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company

Jan 03

The Play On Paratek Pharmaceuticals

Oct 18

Peeking Back In On Paratek Pharmaceuticals

Aug 07

Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial

Jun 16

Paratek shares rise after FDA approves NUZYRA oral only dosing regimen

Jun 01

Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business

Apr 27

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Mar 01
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

Feb 01
Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment

Jan 04

Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale

Dec 01

Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Analyse van de financiële positie

Kortlopende schulden: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Langlopende schulden: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: PRTK has negative shareholder equity, which is a more serious situation than a high debt level.

Schuld verminderen: PRTK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: PRTK has sufficient cash runway for more than a year based on its current free cash flow.

Voorspelling contante baan: Insufficient data to determine if PRTK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Ontdek gezonde bedrijven